Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Ruijin Hospital: Clinical Trials & FDA Approval Profile

Ruijin Hospital (Global / Institutional) sponsors 184 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 126 active protocols (59 recruiting now), 7 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)1.1%
Median Closed Enrollment vs National (145 pts)30 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Ruijin Hospital
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)184
Active Pipeline (Recruiting Now)126 (59)
Completed vs Stopped Early7 / 2 (1.1%)
Median Closed Actual Enrollment30 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Ruijin Hospital
Hospital Research SiteLocationShared Protocols
Ruijin HospitalShanghai44
Ruijin Hospital, Shanghai Jiaotong University School of MedicineShanghai, Shanghai Municipality31
Ruijin Hospital, Shanghai Jiao Tong University School of MedicineShanghai, Shanghai Municipality28

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Ruijin Hospital
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT04208347Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric CancerPhase II/IIIACTIVE NOT RECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Ruijin Hospital Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI